Should I take sermorelin? It can be worth discussing when there's a specific goal and a growth-hormone system that can still respond. But the human evidence is small and mostly decades old, and a few ordinary health questions come first.
To make that concrete, meet Dana, a fictional composite rather than a real patient. She's 54, sleeps badly, feels flat and has noticed her strength slipping. Eight years ago she had thyroid cancer removed, so she takes levothyroxine, a daily thyroid-hormone pill. She has prediabetes, meaning blood sugar above the usual range but below diabetes, and takes estrogen tablets for hot flashes.
Here is roughly the order a provider works through her case. Each step ends in one of three places: worth discussing, a reason a provider may decline, or look at something else first.
1. Should I take sermorelin for what I actually want?
Sermorelin is a lab-made copy of the first 29 building blocks of growth hormone-releasing hormone (GHRH), the brain's signal telling the pituitary gland to release growth hormone. It doesn't supply growth hormone. It asks your own gland for more.
In 11 healthy men aged 64 to 76, six weeks of nightly injections raised overnight growth hormone, but IGF-1 (a steadier blood marker of growth-hormone activity), weight, and scanned muscle and fat didn't change; two of six strength tests improved (Vittone et al., Metabolism, 1997). The largest adult trial randomly assigned 100 adults aged 60 to 85 to sermorelin, then sold as Geref, or placebo for six months. Among the 89 who finished, IGF-1 rose about 34% on sermorelin and some thinking-test scores improved (Vitiello et al., Neurobiology of Aging, 2006).
Neither paper reported sleep or day-to-day energy, Dana's main complaints, and at 54 she's younger than anyone in either trial. Does sermorelin work and sermorelin benefits cover the evidence in full. For Dana: worth discussing, with modest expectations and a measurable goal.
2. Has anyone checked the growth-hormone system?
Dana has never had IGF-1 measured. A baseline helps, but it isn't a diagnosis. A 2021 review notes that IGF-1 alone can't reliably diagnose adult growth-hormone deficiency, and that testing belongs with people at real risk, such as those with past pituitary tumors, surgery or head radiation (Tritos and Biller, Reviews in Endocrine and Metabolic Disorders, 2021).
Her estrogen tablets matter here too. In 16 postmenopausal women, estrogen taken by mouth lowered IGF-1, while an estradiol skin patch didn't (Bellantoni et al., Journal of Clinical Endocrinology & Metabolism, 1996). So her number needs context.
With a pituitary history, this branch would read "look at something else first": an endocrine evaluation, since sermorelin needs a pituitary that can answer.
3. Is the thyroid treated and recently checked?
Dana takes levothyroxine, but her last thyroid test was two years ago. In 14 adults with an underactive thyroid, the growth-hormone response to a test dose of GRF 1-29, the same 29-part fragment sermorelin is made from, roughly doubled once they were on thyroid replacement (Valcavi et al., Clinical Endocrinology, 1986).
An under-treated thyroid can make a medicine look useless, and can explain tiredness by itself. For Dana, this branch reads "not yet": current thyroid labs first.
4. What else is on the medication list?
Dana's two medicines are covered above; other lists need a closer look. Steroid medicines such as prednisone can blunt the response. In six patients starting prednisone, the peak growth-hormone response to a GHRH test dose fell from about 18.8 to 5.0 µg/L within a week, even as IGF-1 rose (Borges et al., Journal of Endocrinological Investigation, 1999).
Other growth-hormone products matter more. Some people arrive already using HGH, MK-677 or a second peptide. The CJC-1295/ipamorelin combination works through two receptors and is its own prescription with its own evidence, not an add-on.
As of September 22, 2026, the day this article was written, the newest human report in PubMed involving sermorelin was a July 3, 2026 case report: a 62-year-old man with about 20 years of self-reported growth hormone and secretagogue use, including sermorelin with GHRP-6, and a bony overgrowth in his neck pressing on his esophagus (Perez et al., Frontiers in Surgery, 2026). The authors offered it as a hypothesis; one case can't show cause. It does show why the full list matters.
5. Is there cancer now, or in the past?
Growth hormone and IGF-1 are growth signals, so the label for Genotropin, a growth-hormone product, lists active cancer as a contraindication (a reason not to use it) and wants any earlier cancer inactive, with treatment complete. Sermorelin isn't growth hormone, but it's meant to raise your own, so providers borrow that caution. Active cancer is a reason a provider may decline.
A past cancer means a longer conversation. An international consensus says growth-hormone replacement might be considered in growth-hormone-deficient adult survivors in remission, after a careful individual risk-benefit review (Boguszewski et al., European Journal of Endocrinology, 2022). The sermorelin studies above weren't designed around survivors, and the Vitiello trial excluded anyone with a personal or strong family history of breast, prostate or colon cancer. Dana may be asked for her oncology records.
6. How steady is blood sugar?
Growth hormone works against insulin. The same Genotropin label, revised in July 2026, warns that it may reduce insulin sensitivity and unmask diabetes, and calls for periodic glucose checks.
The sermorelin studies found no change in fasting glucose over 14 days in 10 older men (Corpas et al., Journal of Clinical Endocrinology & Metabolism, 1992), or in glucose tolerance over six weeks in Vittone's 11. But those men were healthy and not obese, and the Vitiello trial excluded diabetes and obesity outright. None of that speaks for someone with prediabetes. For Dana: worth discussing, with a glucose plan. Uncontrolled diabetes is a reason a provider may decline or wait.
7. Could pregnancy or drug testing change the answer?
Dana is past menopause, so this branch closes quickly for her. For others, no published study has tested sermorelin as a treatment during pregnancy or breastfeeding, and that gap is a reason a provider may decline or wait.
Tested athletes hit a different wall. As of September 22, 2026, the day this article was written, WADA's 2027 Prohibited List, published September 21, 2026 and in force from January 1, 2027, names sermorelin under S2.2.4, growth hormone releasing factors, prohibited in and out of competition. A prescription alone doesn't change that. A tested athlete would need a therapeutic use exemption, formal permission from their anti-doping organization.
8. Sermorelin vs doing nothing, or something else first
Doing nothing is a real option. No trial has compared sermorelin with simply waiting, and Vittone's study had no untreated group. Starting has costs too: the studies used daily injections under the skin, and about 2% of people in the Vitiello trial reported redness or swelling where the needle went in.
Something else may come first. Poor sleep has causes a sleep evaluation can find. A diagnosed growth-hormone deficiency points toward conventional growth-hormone treatment, as an Endocrine Society guideline lays out; sermorelin vs HGH explains the difference. Sermorelin vs ipamorelin and tesamorelin vs sermorelin set out what separates the peptides.
9. What "not everyone qualifies" means for Dana
For Dana, the likely answer today is "not yet": fresh thyroid labs, her oncology records, a clear goal and a glucose plan come first. After that, yes is possible. So is no.
No FDA-approved sermorelin product is currently marketed — Geref was approved in 1997 and withdrawn in 2009 — and the compounded formulation offered here is not FDA-approved. Promise offers sermorelin by prescription, after a licensed provider reviews your request. The agency later determined Geref wasn't withdrawn for safety or effectiveness reasons (Federal Register, March 4, 2013). A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. A decline, or a request for more information, is a clinical outcome, not a broken process.
